RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DO BLOOD LEVELS OF APOA-1 REALLY MATTER SO MUCH????On the subject of lack of communications......
The recently published paper on the ability of RVX-208 to decrease atherosclerotic plaque in apoE-/- mice was first reported at ATVB conference over four years ago (news release 4/9/2010). That's quite a lapse in time between completion of a study and publication. This exemplifies how much data and how much of a story they still have to tell. The ASSERT trial has been published. But SUSTAIN and ASSURE have not. Furthermore, pre-clinical RVX/Zenith studies on Alzheimers, Diabetes and Inflammation are also mostly unpublished. We've seen glimpses of many of these data in RVX webcasts over the past few years, and some have been presented as talks or posters at certain scientific meetings. But aside from a few shout outs in some reveiws on BET inhibitors, nothing big has been published recently. So in addition to lack of recent RVX webcasts, and lack of stock analyst coverage, there has also been a dearth of scientific publication.
BDAZ